dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Iacoboni García-Calvo, Gloria |
dc.contributor.author | Martinez-Cibrian, Nuria |
dc.contributor.author | Bailén, Rebeca |
dc.contributor.author | Corral, Lucia Lopez |
dc.contributor.author | Sanchez, Jose M. |
dc.contributor.author | Abrisqueta Costa, Pablo |
dc.contributor.author | Barba Suñol, Pere |
dc.contributor.author | Villacampa Javierre, Guillermo |
dc.date.accessioned | 2022-01-11T12:09:04Z |
dc.date.available | 2022-01-11T12:09:04Z |
dc.date.issued | 2021-05 |
dc.identifier.citation | Iacoboni G, Villacampa G, Martinez‐Cibrian N, Bailén R, Lopez Corral L, Sanchez JM, et al. Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma. Cancer Med. 2021 May;10(10):3214–3223. |
dc.identifier.issn | 2045-7634 |
dc.identifier.uri | https://hdl.handle.net/11351/6761 |
dc.description | Clinical cancer research; Hematological cancer; Non-Hodgkin's lymphoma |
dc.description.abstract | Tisagenlecleucel (tisa-cel) is a second-generation autologous CD19-targeted chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). The approval was based on the results of phase II JULIET trial, with a best overall response rate (ORR) and complete response (CR) rate in infused patients of 52% and 40%, respectively. We report outcomes with tisa-cel in the standard-of-care (SOC) setting for R/R LBCL. Data from all patients with R/R LBCL who underwent leukapheresis from December 2018 until June 2020 with the intent to receive SOC tisa-cel were retrospectively collected at 10 Spanish institutions. Toxicities were graded according to ASTCT criteria and responses were assessed as per Lugano 2014 classification. Of 91 patients who underwent leukapheresis, 75 (82%) received tisa-cel therapy. Grade 3 or higher cytokine release syndrome and neurotoxicity occurred in 5% and 1%, respectively; non-relapse mortality was 4%. Among the infused patients, best ORR and CR were 60% and 32%, respectively, with a median duration of response of 8.9 months. With a median follow-up of 14.1 months from CAR T-cell infusion, median progression-free survival and overall survival were 3 months and 10.7 months, respectively. At 12 months, patients in CR at first disease evaluation had a PFS of 87% and OS of 93%. Patients with an elevated lactate dehydrogenase showed a shorter PFS and OS on multivariate analysis. Treatment with tisa-cel for patients with relapsed/refractory LBCL in a European SOC setting showed a manageable safety profile and durable complete responses. |
dc.language.iso | eng |
dc.publisher | Wiley |
dc.relation.ispartofseries | Cancer Medicine;10(10) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Cèl·lules B - Tumors - Tractament |
dc.subject | Teràpia cel·lular |
dc.subject.mesh | Lymphoma, Large B-Cell, Diffuse |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Receptors, Antigen, T-Cell |
dc.subject.mesh | /therapeutic use |
dc.title | Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1002/cam4.3881 |
dc.subject.decs | linfoma de células B grandes difuso |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | receptores de antígenos de linfocitos T |
dc.subject.decs | /uso terapéutico |
dc.relation.publishversion | https://doi.org/10.1002/cam4.3881 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Iacoboni G, Abrisqueta P, Barba P] Servei d’Hematologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Villacampa G] Oncology Data Science, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Martinez-Cibrian N] Department of Hematology, University Hospital Virgen del Rocio, Sevilla, Spain. [Bailén R] Department of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain. Gregorio Marañón Health Research Institute (IiSGM), Madrid, Spain. [Lopez Corral L] Hematology Department, Hospital Clínico Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain. Centro de Investigación del Cáncer-IBMCC, Salamanca, Spain. [Sanchez JM] Hematology Department, Hospital 12 de Octubre, Madrid, Spain |
dc.identifier.pmid | 33932100 |
dc.identifier.wos | 000645922100001 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PERIS2016-2020/BDNS357800 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |